Literature DB >> 23143250

Crystallization, X-ray diffraction analysis and SIRAS phasing of human α-L-iduronidase.

Nobuo Maita1, Hisaaki Taniguchi, Hitoshi Sakuraba.   

Abstract

Human lysosomal α-L-iduronidase, whose deficiency causes mucopolysaccharidosis type I, was crystallized using sodium/potassium tartrate and polyethylene glycol 3350 as a precipitant. Using synchrotron radiation, a native data set was collected from a single crystal at 100 K to 2.3 Å resolution. The crystal belonged to space group R3 with unit-cell dimensions of a=b=259.22, c=71.83 Å. To obtain the phase information, mercury-derivative crystals were prepared and a single-wavelength anomalous dispersion (SAD) data set was collected at the Hg peak wavelength. Phase calculation with the single isomorphous replacement with anomalous scattering (SIRAS) method successfully yielded an interpretable electron-density map.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23143250      PMCID: PMC3515382          DOI: 10.1107/S1744309112040432

Source DB:  PubMed          Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun        ISSN: 1744-3091


  15 in total

1.  Methods used in the structure determination of bovine mitochondrial F1 ATPase.

Authors:  J P Abrahams; A G Leslie
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  1996-01-01

2.  Enzyme-substrate complex structures of a GH39 beta-xylosidase from Geobacillus stearothermophilus.

Authors:  Mirjam Czjzek; Alon Ben David; Tsafrir Bravman; Gil Shoham; Bernard Henrissat; Yuval Shoham
Journal:  J Mol Biol       Date:  2005-09-20       Impact factor: 5.469

Review 3.  Structural aspects of therapeutic enzymes to treat metabolic disorders.

Authors:  Tse Siang Kang; Raymond C Stevens
Journal:  Hum Mutat       Date:  2009-12       Impact factor: 4.878

4.  Solvent content of protein crystals.

Authors:  B W Matthews
Journal:  J Mol Biol       Date:  1968-04-28       Impact factor: 5.469

5.  A homology model for human alpha-l-iduronidase: insights into human disease.

Authors:  Brian P Rempel; Lorne A Clarke; Stephen G Withers
Journal:  Mol Genet Metab       Date:  2005-02-10       Impact factor: 4.797

6.  Crystal structure of beta-D-xylosidase from Thermoanaerobacterium saccharolyticum, a family 39 glycoside hydrolase.

Authors:  Jin Kuk Yang; Hye Jin Yoon; Hyung Jun Ahn; Byung Il Lee; Jean-Denis Pedelacq; Elaine C Liong; Joel Berendzen; Maris Laivenieks; Claire Vieille; Gregory J Zeikus; David J Vocadlo; Stephen G Withers; Se Won Suh
Journal:  J Mol Biol       Date:  2004-01-02       Impact factor: 5.469

7.  Experimental phasing with SHELXC/D/E: combining chain tracing with density modification.

Authors:  George M Sheldrick
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2010-03-24

8.  Features and development of Coot.

Authors:  P Emsley; B Lohkamp; W G Scott; K Cowtan
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2010-03-24

Review 9.  Molecular genetics of mucopolysaccharidosis type I: diagnostic, clinical, and biological implications.

Authors:  H S Scott; S Bunge; A Gal; L A Clarke; C P Morris; J J Hopwood
Journal:  Hum Mutat       Date:  1995       Impact factor: 4.878

10.  Identification and molecular characterization of alpha-L-iduronidase mutations present in mucopolysaccharidosis type I patients undergoing enzyme replacement therapy.

Authors:  G Yogalingam; X-H Guo; V J Muller; D A Brooks; P R Clements; E D Kakkis; J J Hopwood
Journal:  Hum Mutat       Date:  2004-09       Impact factor: 4.878

View more
  2 in total

1.  Human α-L-iduronidase uses its own N-glycan as a substrate-binding and catalytic module.

Authors:  Nobuo Maita; Takahiro Tsukimura; Takako Taniguchi; Seiji Saito; Kazuki Ohno; Hisaaki Taniguchi; Hitoshi Sakuraba
Journal:  Proc Natl Acad Sci U S A       Date:  2013-08-19       Impact factor: 11.205

2.  The discovery of a new antibody for BRIL-fused GPCR structure determination.

Authors:  Hikaru Miyagi; Hidetsugu Asada; Michihiko Suzuki; Yuichi Takahashi; Mai Yasunaga; Chiyo Suno; So Iwata; Jun-Ichi Saito
Journal:  Sci Rep       Date:  2020-07-15       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.